Fulford (India) Peer Comparison

NSE: FULFORD | BSE: 506803

₹2,362.00

₹1.00 (0.04%)

As on 30-Jul-2015IST

Market cap

₹921 Cr

Revenue (TTM)

₹109 Cr

P/E Ratio

32.5

P/B Ratio

6.1

Div. Yield

0 %

Edit

	Fulford (India)	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	921	37,857	27,713	26,763	28,045
Revenue (₹ Cr)	109	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	28.33	414.00	288.22	387.35	-371.81
Net Margin (%)	23.93	11.23	14.79	26.01	-3.93
RoE (%)	13.36	8.38	29.77	25.18	-3.85
Price to Earnings	32.51	92.56	96.15	69.30	--
Price-To-Book	6.15	7.52	20.65	15.51	3.50

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Fulford (India)	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	109.36	2,843.99	263.02	239.64	--
Total Income	118.42	2,904.07	281.09	242.49	--
Total Expenditure	79.28	2,746.23	182.42	198.63	--
EBITDA	30.07	97.76	80.60	41.02	--
Depreciation	0.09	224.14	18.45	3.52	--
EBIT	29.99	-126.38	62.15	37.50	--
Interest	0.29	275.74	6.20	5.59	--
Other Income	9.06	60.08	18.07	2.84	--
Exceptional Items	--	--	--	--	--
Profit before Tax	38.76	-342.04	74.01	34.75	--
Provision for Tax	10.43	-204.09	24.60	7.28	--
Profit after Tax	28.33	-137.95	49.41	27.47	--

Liabilities (₹ Cr)

	Fulford (India)	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	225.93	2,671.67	340.50	111.81	--
Minority Interest	--	385.79	--	--	--
Non-Current Liabilities	-2.88	1,194.85	9.30	25.46	--
Current Liabilities	26.61	3,497.18	77.54	94.61	--
Total Liabilities	254.91	8,147.66	430.39	231.89	--

Assets (₹ Cr)

	Fulford (India)	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	78.87	5,319.66	162.50	104.93	--
Current Assets	170.80	2,400.54	264.84	121.04	--
Total Assets	254.91	8,147.66	430.39	231.89	--
Total Debt*	0.00	3,213.23	30.27	59.42	--
Net Current Assets	144.19	-1,096.64	187.31	26.42	--
Contingent Liabilities	143.54	641.08	46.45	0.07	--

Cashflow (₹ Cr)

	Fulford (India)	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	3.65	648.96	5.47	27.08	--
Cash Flow from Investing Activities	69.78	-155.53	-84.34	-23.94	--
Cash from Financing Activities	-0.77	-679.58	80.07	0.19	--
Net Cash Inflow / Outflow	72.66	-186.15	1.21	3.33	--

Ratios

Profitability Ratios

	Fulford (India)	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	18.42	-1.11	26.00	27.09	--
ROE (%)	13.36	-5.22	18.67	29.78	--
ROA (%)	12.02	-1.80	13.65	12.34	--
EBIT Margin (%)	35.79	5.55	37.51	18.30	--
Net Margin (%)	23.93	-4.75	17.58	11.33	--
Cash Profit Margin (%)	25.99	3.03	25.80	12.93	--

Growth Ratios

	Fulford (India)	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	9.65	-20.24	71.02	0.47	--
EBIT Growth (%)	-2.31	1,004.01	159.60	3.29	--
Net Profit Growth (%)	1.95	55.76	168.16	17.92	--
EPS Growth (%)	1.95	64.44	148.52	17.92	--
Book Value Growth (%)	14.07	-0.03	68.83	34.77	--

Valuation Ratios

	Fulford (India)	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	0.00	0.00	0.00	0.00	--
Price / Book Value	0.00	0.72	0.00	0.00	--
Dividend Yield (%)	--	0.00	--	--	--
EV/EBITDA	-3.40	30.78	0.00	1.51	--
Market Cap (₹ Cr)	0.00	1,913.03	0.00	0.00	--

Solvency Ratios

	Fulford (India)	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	0.00	1.22	0.09	0.56	--
Short term debt to equity ratio	--	0.34	0.06	0.30	--
Current Ratio	6.42	0.69	3.42	1.28	--
Quick Ratio	6.34	0.48	2.93	0.73	--
Interest Coverage	134.58	-0.24	12.93	7.22	--

Operating Efficiency Ratios

	Fulford (India)	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	16.09	43.70	53.26	23.54	--
Asset Turnover	0.46	0.37	0.73	1.08	--
Receivable days	34.64	161.49	155.79	100.90	--
Inventory Days	23.56	98.54	39.61	69.31	--
Payable days	176.33	263.19	159.03	169.65	--
Cash Conversion Cycle	-118.13	-3.16	36.37	0.56	--